Loading
A phase 3 trial of Nivolumab in melanoma, run by HUYABIO International, LLC., active and no longer recruiting.
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma is a phase 3 interventional study registered as NCT04674683 by HUYABIO International, LLC., with 450 participants enrolled, started 2021-08-12 and due to reach its primary completion in 2026-07. Interventions recorded: HBI-8000 in combination with nivolumab, Placebo in combination with nivolumab. Conditions listed: Unresectable or Metastatic Melanoma, Progressive Brain Metastasis. No results are recorded here; the registry entry is the source.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Immune checkpoint inhibitors.